Cytokinetics Inc (NASDAQ:CYTK)

CAPS Rating: 3 out of 5

A biopharmaceutical company, focused on developing small molecule therapeutics for the treatment of cardiovascular diseases and cancer.

Recs

0
Player Avatar pchop123 (79.53) Submitted: 1/14/2013 2:25:33 PM : Outperform Start Price: $6.66 CYTK Score: -10.08

speculative at this price point, but it will likely continue to climb upward

Featured Broker Partners


Advertisement